Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3-ABCB1 Signaling in Hepatocellular Carcinoma.

Beiyuan Hu,Tiantian Zou,Wei Qin,Xiaotian Shen,Yinghan Su,Jianhua Li, Yang Chen,Ze Zhang,Haoting Sun,Yan Zheng,Chao-Qun Wang,Zhengxin Wang,Tian-En Li,Shun Wang, Le Zhu,Xufeng Wang,Yan Fu,Xudong Ren,Qiongzhu Dong,Lun-Xiu Qin

Cancer research（2022）

引用 39|浏览12

暂无评分

摘要

HCC cells acquire resistance to lenvatinib by activating the EGFR-STAT3-ABCB1 pathway, identifying combined treatment with erlotinib as a strategy to overcome acquired resistance and improve the clinical benefit of lenvatinib.

查看译文

关键词

hepatocellular carcinoma,egfr,stat3–abcb1

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要